Eli Lilly will reveal approximately 50 studies at the end of the month at the 44th Annual Meeting of the American Society of Clinical Oncology in Orlando, Florida. The majority of the 50 presentations will support Lilly’s ongoing study in thoracic cancer research.
Among the notable bits of information to be discussed are the latest research findings on ALIMTA, which is pemetrexed (a chemotherapy drug) for injection. ALIMTA, a treatment for malignant pleural mesothelioma, is given with cisplatin, another chemotherapy drug, when surgery is not an option.
For more information, including a listing of studies of note for ALIMTA and the times they will be presented, see Eli Lilly’s press release
